S&P 500   3,118.62 (-0.11%)
DOW   27,935.72 (-0.36%)
QQQ   203.08 (+0.00%)
CGC   14.92 (+4.92%)
BABA   184.22 (-0.21%)
T   38.34 (-3.28%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
BAC   32.84 (-0.36%)
DIS   147.35 (-0.20%)
S&P 500   3,118.62 (-0.11%)
DOW   27,935.72 (-0.36%)
QQQ   203.08 (+0.00%)
CGC   14.92 (+4.92%)
BABA   184.22 (-0.21%)
T   38.34 (-3.28%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
BAC   32.84 (-0.36%)
DIS   147.35 (-0.20%)
S&P 500   3,118.62 (-0.11%)
DOW   27,935.72 (-0.36%)
QQQ   203.08 (+0.00%)
CGC   14.92 (+4.92%)
BABA   184.22 (-0.21%)
T   38.34 (-3.28%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
BAC   32.84 (-0.36%)
DIS   147.35 (-0.20%)
S&P 500   3,118.62 (-0.11%)
DOW   27,935.72 (-0.36%)
QQQ   203.08 (+0.00%)
CGC   14.92 (+4.92%)
BABA   184.22 (-0.21%)
T   38.34 (-3.28%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
BAC   32.84 (-0.36%)
DIS   147.35 (-0.20%)
Log in

PRA Health Sciences Stock Price, Forecast & Analysis (NASDAQ:PRAH)

$106.63
+0.91 (+0.86 %)
(As of 11/19/2019 11:25 AM ET)
Today's Range
$105.42
Now: $106.63
$106.89
50-Day Range
$93.39
MA: $99.15
$105.49
52-Week Range
$82.12
Now: $106.63
$121.98
Volume2,976 shs
Average Volume461,078 shs
Market Capitalization$6.74 billion
P/E Ratio27.13
Dividend YieldN/A
Beta1.11
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.87 billion
Cash Flow$5.95 per share
Book Value$16.18 per share

Profitability

Net Income$153.90 million

Miscellaneous

Employees16,400
Market Cap$6.74 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.


PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings results on Wednesday, October, 30th. The medical research company reported $1.32 EPS for the quarter, topping the Zacks' consensus estimate of $1.29 by $0.03. The medical research company had revenue of $780.70 million for the quarter, compared to analysts' expectations of $771.64 million. PRA Health Sciences had a return on equity of 27.73% and a net margin of 8.00%. PRA Health Sciences's revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business earned $1.13 earnings per share. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for PRA Health Sciences.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of $5.07-$5.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.07. The company issued revenue guidance of $3.02-$3.10 billion, compared to the consensus revenue estimate of $3.06 billion.

What price target have analysts set for PRAH?

9 equities research analysts have issued twelve-month price objectives for PRA Health Sciences' stock. Their forecasts range from $100.00 to $126.00. On average, they expect PRA Health Sciences' share price to reach $116.75 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

What is the consensus analysts' recommendation for PRA Health Sciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

News coverage about PRAH stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PRA Health Sciences earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for PRA Health Sciences.

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,120,000 shares, an increase of 9.3% from the September 30th total of 1,940,000 shares. Based on an average trading volume of 500,400 shares, the days-to-cover ratio is presently 4.2 days. Currently, 3.4% of the shares of the company are sold short. View PRA Health Sciences' Current Options Chain.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Applied Materials (AMAT), Paypal (PYPL), Lam Research (LRCX), Netflix (NFLX), GrubHub (GRUB), Veeva Systems (VEEV) and ABIOMED (ABMD).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
  • Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (1.12%), Massachusetts Financial Services Co. MA (0.98%), Carillon Tower Advisers Inc. (0.95%), Vaughan Nelson Investment Management L.P. (0.83%), Stephens Investment Management Group LLC (0.69%) and Artemis Investment Management LLP (0.36%). Company insiders that own PRA Health Sciences stock include David W Dockhorn, Fund Holdings LP Kkr, Linda Baddour and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which major investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Mackay Shields LLC, Sloane Robinson LLP, Icon Advisers Inc. Co., SG Americas Securities LLC, Meritage Portfolio Management, Bowling Portfolio Management LLC and Scout Investments Inc.. View Insider Buying and Selling for PRA Health Sciences.

Which major investors are buying PRA Health Sciences stock?

PRAH stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Kornitzer Capital Management Inc. KS, Vaughan Nelson Investment Management L.P., Reilly Financial Advisors LLC, Tygh Capital Management Inc., Carillon Tower Advisers Inc., State of New Jersey Common Pension Fund D and California Public Employees Retirement System. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $106.17.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $6.72 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is http://www.prahs.com/.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel